Precision Biosciences (DTIL) Share-based Compensation (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.5 million, down 45.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 108.1% YoY), and the FY2025 annual result was $259000.0, down 97.95% from the prior year.
• Share-based Compensation improved to $1.5 million in Q1 2026 per DTIL's latest filing, from -$7.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $5.1 million in Q2 2022 and troughed at -$7.9 million in Q4 2025.
• A 5-year average of $2.8 million and a median of $3.1 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 31.88% in 2022, then slumped 320.83% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $4.5 million in 2022, then plunged by 34.55% to $3.0 million in 2023, then increased by 20.28% to $3.6 million in 2024, then slumped by 320.83% to -$7.9 million in 2025, then soared by 119.64% to $1.5 million in 2026.
• Business Quant data shows DTIL's Share-based Compensation at $1.5 million in Q1 2026, -$7.9 million in Q4 2025, and $2.4 million in Q3 2025.